KFDA okays phase 1 study of functional combination drug
Published: 2009-12-29 06:57:00
Updated: 2009-12-29 06:57:00
Hanall Pharm said on December 23 its has received approval from the Korea Food and Drug Administration to conduct phase 1 clinical trial of a combination drug (amlodipine plus atorvastatin) for the treatment of hypertension and hyperlipidemia.
Hanall officials said the approval comes after suc...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
